Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery?

Nature Clinical Practice Oncology volume 3, pages 416–417 (2006)Cite this article

boxed-textArmstrong DK et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43

The GOG 172 intraperitoneal chemotherapy regimen represents a new standard of care for patients with optimally resected stage III ovarian cancer but should be offered on an individualized basis

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. National Institutes of Health (online January 2006) NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer [http://www.nih.gov/news/pr/jan2006/nci-04.htm] (accessed 21 April 2006)

  2. Alberts DS et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955

    Article  CAS  Google Scholar 

  3. Markman M et al. (2001) Phase III trial of standard intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001–1007

    Article  CAS  Google Scholar 

  4. Ozols RF et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194–3200

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Director of the Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, CT, USA

    Carolyn Runowicz

Authors
  1. Carolyn Runowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carolyn Runowicz.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Runowicz, C. Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery?. Nat Rev Clin Oncol 3, 416–417 (2006). https://doi.org/10.1038/ncponc0556

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0556

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing